Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration
- 9 May 2005
- journal article
- clinical trial
- Published by Elsevier in Ophthalmology
- Vol. 112 (6) , 1048-1053.e4
- https://doi.org/10.1016/j.ophtha.2005.01.043
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: